JAMA Neurology Examines Rituxan

This study, recently published in the journal JAMA Neurology, examined the use of Rituximab as a first-line MS treatment in Sweden. Rituximab is already extensively used in Sweden but this study showed the improved efficacy and safety of using Rituximab as a first MS treatment as compared to other MS drugs. However, as Rituximab is not FDA-approved in the United States for MS, its use early in MS is limited due to restrictions by insurance companies.

https://www.medpagetoday.com/neuro…/multiplesclerosis/70393…